New drug combo aims to wipe out stomach cancer before surgery
NCT ID NCT07483567
First seen Mar 25, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tests whether adding a new drug called IBI343 to standard immunotherapy and chemotherapy can help eliminate stomach cancer more effectively before and after surgery. It involves 90 adults with a specific type of stomach cancer that has not spread widely. Participants will receive the drug combination either before and after surgery, and researchers will check how many have no cancer left after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI343 (a drug targeting CLDN18.2) combined with sintilimab (an immunotherapy) and chemotherapy (oxaliplatin and S-1)
What this could lead to
If successful, this combination could improve the chance of eliminating all cancer before and after surgery for people with a specific type of gastric cancer.
What could go wrong
This is an early phase 2 trial with only 90 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it will improve long-term survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.